An effort to map the way the brains of those with autism are genetically unique from neurotypical individuals has found that the differences go well beyond regions involved in social behavior and language. In fact, the distinctions are particularly profound in the visual cortex, according to a study published Wednesday in Nature by researchers from the University of California, Los Angeles (UCLA).

There are many different types of epileptic seizures, but all of them spur from batches of overactive neurons. While gene therapies have shown promise in treating epilepsy, most of those developed so far tend to impact cells across an entire region of the brain rather than selecting for pathologically excited neurons. Other strategies such as medication and electrographic seizure detectors have limits, too.

NextCure dropped one of its cancer antibodies after the therapy failed to make an impact in a phase 2 trial.

An overloaded and understaffed supply chain has led to shortage after shortage of crucial medical gear since the start of the COVID-19 pandemic.

Abeona Therapeutics has overcome an FDA clinical hold to show that its cell therapy can heal wounds in patients with a rare connective tissue disease, teeing up an FDA filing in the new year.

The cat’s out of the bag: Regeneron is leaving two drugs behind, including an NGF inhibitor targeting chronic pain and a cat allergy therapy.

Gilead Sciences and Arcus are slimming down a phase 3 TIGIT trial to compare the lung cancer combo therapy to just Merck’s Keytruda, ditching a chemotherapy arm.

Biotechs announcing strategic reviews has become a depressingly common sign in these straightened times, and that’s certainly the case for Rubius Therapeutics and Tricida.

GSK has halted two phase 3 trials of its uncomplicated urinary tract infection (UTI) treatment early after the antibiotic hit its goals, teeing up the Big Pharma to submit the candidate for FDA approval next year.

Exscientia is planting its flag in antibody design. The company announced the expansion of its artificial intelligence-powered drug discovery platforms from small molecule medicines to the construction of larger and more complex biologic therapies.